Status and phase
Conditions
Treatments
About
Type 1 diabetes is caused by an autoimmune process resulting in a selective destruction of the pancreatic insulin-secreting beta-cell. DiaPep277® is a small, lyophilized powder containing 24 Amino-acids. We have proved in former studies that DiaPep277® can slow down beta cells destruction in the pancreas and therefore decelerate the progress of Diabetes.
The objective of the study is to assess the efficacy and safety of administrating DiaPep277® in type 1 diabetes patients.
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
The subject has any significant diseases or conditions, including psychiatric disorders and substance abuse that, in the opinion of the Investigator, are likely to affect the subject's response to treatment or the ability to complete the study.
The subject has a history of any kind of malignant tumor (not including basal cell skin cancer).
The subject has clinical evidence of any diabetes-related complication that in the opinion of the Investigator would interfere with the subject's participation in and/or completion of the study.
Subject has history of endogenous allergic reactivity:
The subject has known allergy to lipid emulsions.
The subject has a known immune deficiency from any disease, or a condition associated with an immune deficiency.
The subject is receiving immunosuppressive or immunomodulating agents or cytotoxic therapy or any medication that in the opinion of the Investigator might interfere with the study.
The subject has any of the following clinically significant laboratory abnormalities:
The subject is a known or suspected drug abuser.
The subject is known to test positive for HIV antibodies.
The subject has chronic hematologic disease.
The subject has liver disease such as cirrhosis or chronic active hepatitis.
Primary purpose
Allocation
Interventional model
Masking
0 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal